UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000018882
Receipt No. R000021841
Scientific Title Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502)
Date of disclosure of the study information 2015/09/01
Last modified on 2020/03/05 18:59:30

No. Disposal Last modified on Item of update
1 Insert 2015/09/01 22:39:01
2 Update 2015/09/02 13:32:09 Acronym
Acronym
3 Update 2015/09/02 13:43:32 Interventions/Control_1
Interventions/Control_1
4 Update 2015/09/02 13:48:16 Key inclusion criteria
Key inclusion criteria
5 Update 2015/11/18 13:21:13 Recruitment status
Date of protocol fixation
Anticipated trial start date
6 Update 2015/11/18 13:32:24 Public title
7 Update 2015/12/13 16:54:48 Other related information
8 Update 2016/02/17 16:22:18 Other related information
9 Update 2016/07/24 15:39:42 Other related information
10 Update 2016/08/17 12:14:05 Name of primary sponsor
Organization
11 Update 2017/09/02 11:47:03 Other related information
12 Update 2018/03/03 10:13:44 Other related information
13 Update 2018/09/03 22:35:48 Recruitment status
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other related information
14 Update 2019/09/15 15:25:56 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
15 Update 2019/09/15 15:29:54 Publication of results
Number of participants that the trial has enrolled
Results
Results
Results date posted
16 Update 2019/09/15 15:30:57 Date of IRB
Date analysis concluded
17 Update 2020/03/05 18:59:30 URL releasing protocol
URL related to results and publications
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures


Contact us.